

- Group IV** Claims 1-3 and 5-8 drawn to compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, LAG being -O-(SO₂)-OH, and pharmaceutical compositions comprising such compounds, classified in class 540, subclass 200;
- Group V** Claims 1-3 and 5-8 drawn to compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, and pharmaceutical compositions comprising such compounds, classified in class 540, subclass 200;
- Group VI** Claims 9-12, drawn to methods for the treatment of impaired lipid metabolism, including hyperlipidemia, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being a sugar residue, disugar residue, trisugar residue, tetrasugar residue, a sugar acid or an amino sugar, classified in class 514, subclass 25;
- Group VII** Claims 9-12, drawn to methods for the treatment of impaired lipid metabolism, including hyperlipidemia, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being an amino acid residue or an oligopeptide residue, classified in 514, subclass 2*;
- Group VIII** Claims 9-12, drawn to methods for the treatment of impaired lipid metabolism, including hyperlipidemia, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being a trialkylammoniumalkyl radical, classified in class 514, subclass 210.02;
- Group IX** Claims 9-12, drawn to methods for the treatment of impaired lipid metabolism, including hyperlipidemia, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being -O-(SO₂)-OH, classified in class 514, subclass 210.02;
- Group X** Claims 9-12, drawn to methods for the treatment of impaired lipid metabolism, including hyperlipidemia, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, classified in class 514, subclass 210.02;
- Group XI** Claim 13, drawn to methods for controlling serum cholesterol concentration, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being a sugar residue, disugar residue, trisugar residue, tetrasugar residue, a sugar acid or an amino acid sugar, classified in class 514, subclass 25;

- Group XII** Claim 13, drawn to methods for controlling serum cholesterol concentration, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being an amino acid residue or an oligopeptide residue, classified in class 514, subclass 2⁺;
- Group XIII** Claim 13, drawn to methods for controlling serum cholesterol concentration, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being a trialkylammoniumalkyl radical, classified in class 514, subclass 210.02;
- Group XIV** Claim 13, to methods for controlling serum cholesterol concentration, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, LAG being -O-(SO₂)-OH, classified in class 514, subclass 210.02;
- Group XV** Claim 13, drawn to methods for controlling serum cholesterol concentration, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-LAG radical, classified in class 514, subclass 210.02;
- Group XVI** Claims 14-15, drawn to methods for treating insulin resistance, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, LAG being a sugar residue, disugar residue, trisugar residue, tetrasugar residue, a sugar acid or an amino sugar, classified in class 514, subclass 25;
- Group XVII** Claims 14-15, drawn to methods for treating insulin resistance, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, LAG being an amino acid residue or an oligopeptide residue, classified in class 514, subclass 2⁺;
- Group XVIII** Claims 14-15, drawn to methods for treating insulin resistance, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, LAG being a trialkylammoniumalkyl radical, classified in class 514, subclass 210.02;
- Group XIX** Claims 14-15, drawn to methods for treating insulin resistance, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, LAG being -O-(SO₂)-OH, classified in class 514, subclass 210.02;
- Group XX** Claims 14-15, drawn to methods for treating insulin resistance, using compounds of the Formula I with only one (C₀-C₃₀)alkylene-(LAG) radical, classified in class 514, subclass 210.02;
- Group XXI** Claims 16-17, drawn to methods for the treatment of an arteriosclerotic manifestation, using compounds of the Formula I